3. Financing for TB prevention, diagnostic and treatment services
3.1. Budgets required for national strategic plans for TB
3.1.1 Source of funding and funding gap reported for the TB-specific budget (current US$)
3.1.2 Source of funding and funding gap reported for the TB-specific budget (%)
3.1.3 Gap between the budget required and expected funding by line-item (current US$)
3.2. Funding available for TB prevention, diagnostic and treatment services
3.2.1 Funding available by source of funding (current US$)
3.2.2 Funding available by line item (current US$)
3.2.3 Funding available and actual expenditure (current US$)
Metadata
Glossary and definitions
| Budget required | Budget required is the amount of funding required to carry out TB national strategic plans, which includes expected disbursements from domestic funding, international funding from donors and funding gaps. Sources: data reported by NTPs and estimates produced by the WHO Global Programme on Tuberculosis & Lung Health. |
|---|---|
| Expected funding | Expected funding is a portion of the budget required for TB national strategic plans, which consists of expected (or committed) funding from domestic funding sources (e.g. the national or peripheral government, loans) and also from international funding sources (e.g. The Global Fund, the United States Agency for International Development (USAID)). The difference between the budget required and the expected funding is considered as funding gaps. Sources: data reported by NTPs and estimates produced by the WHO Global Programme on Tuberculosis & Lung Health. |
| Funding available | Funding available is the amount of funding actually received by national TB programmes from sources of funding including the national government and international donors. Sources: data reported by NTPs and estimates produced by the WHO Global Programme on Tuberculosis & Lung Health. The data sources, boundaries, accounting rules, and estimation methods used in this report are different from those of the system of Health Accounts 2011 (SHA2011). The TB funding data reported here are thus not comparable with the disease expenditure data, including for TB, that are reported in WHO's Global Health Expenditure Database. |
| Actual expenditure | Actual expenditure is the amount of funding that was actually spent on interventions and activities, out of the available (i.e., received) funding. Sources: data reported by NTPs and estimates produced by the WHO Global Programme on Tuberculosis & Lung Health. The data sources, boundaries, accounting rules, and estimation methods used in this report are different from those of the system of Health Accounts 2011 (SHA2011). The TB funding data reported here are thus not comparable with the disease expenditure data, including for TB, that are reported in WHO's Global Health Expenditure Database. |
| Domestic source of funding | Expected funding from domestic sources, including loans (US Dollars). |
| Global Fund source of funding | Expected funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria (US Dollars). |
| International source of funding (excluding Global Fund) | Expected funding from sources other than the Global Fund. |
| Budget gap | The difference between funding required for the implementation of national strategic plan for TB and available funding as reported by national TB programmes (US Dollars). |
| Percentage of domestic funding | Expected funding from domestic sources over total funding required for the implementation of national strategic plan for TB expressed as percentage. |
| Percentage of Global Fund funding | Expected funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria over total funding required for the implementation of national strategic plan for TB expressed as percentage. |
| Percentage of budget gap | Budget gap over the total funding required for the implementation of national strategic plan for TB expressed as percentage. |
| DS-TB line item | Drug-susceptible TB line-item includes funding reported by NTPs for the following items: laboratory equipment and supplies, anti-TB drugs, programme management (including staff and activities); operational research and surveys; patient support; and miscellaneous items. |
| DR-TB line item | Drug-resistant TB line-item includes funding reported by NTPs for the following items: anti-TB drugs required for treatment of multidrug and rifampicin-resistant TB (MDR/RR-TB, which includes people with pre-extensively drug-resistant TB and extensively drug-resistant TB); any programme management cost specifically required for the provision of care to people with drug-resistant TB (excluding staff). The categories for which funding is reported to WHO do not allow for funding for the diagnosis of drug-resistant TB specifically to be distinguished. In data analysis, the category of laboratory supplies and equipment is allocated to drug-susceptible TB. Rapid tests recommended by WHO can detect TB and RR-TB simultaneously. |
| TB/HIV line item | TB/HIV line item includes funding reported by NTPs for the collaboration between TB and HIV programmes aimed at reducing the impact of HIV-related TB. Activities include TB/HIV coordinating bodies, joint TB/HIV training and planning, HIV testing for people with TB, HIV surveillance among people with TB, co-trimoxazole preventive therapy, joint TB/HIV education and communication, and antiretroviral treatment for people with TB. |
| TB preventive treatment | TB preventive treatment line item includes funding reported by NTPs for drugs used in TB preventive treatment, as per latest WHO guidance, e.g. 6H (six months of daily isoniazid monotherapy), 9H (nine months of daily isoniazid monotherapy), 4R (four months of daily rifampicin monotherapy), 3HR (three months of daily rifampicin plus isoniazid) and Levofloxacin. |
Copyright and licensing
| Copyright | Attribution 4.0 International (CC BY 4.0) |
|---|---|
| License | The World Health Organization (“WHO”) encourages public access and use of the data that it collects and publishes on its web site data.who.int. The data are organized in datasets and made available in machine-readable format (“Datasets”). The Datasets have been compiled from data provided by WHO’s Member States under the WHO policy on the use and sharing of data collected by WHO in Member States outside the context of public health emergencies. Use of the data derived from the Datasets, which may appear in formats such as tables and charts, is also subject to these Terms and Conditions. Datasets may include data describing the Dataset called “Metadata”. If any datasets are credited to a source other than WHO, then those materials are not covered by these Terms and Conditions, and permission should be sought from the source provided. You are responsible for determining if this is the case, and if so, you are responsible for obtaining any necessary permission from the sources indicated. The risk of claims resulting from infringement of any third-party-owned component in the materials rests solely with you. You may use our application programming interfaces (“APIs”) to facilitate access to the Datasets, whether through a separate web site or through another type of software application. By using the Datasets or any presentations of data derived from them, or by using our APIs in connection with the Datasets, you agree to be bound by these Terms and Conditions, as may be amended from time to time by WHO at its sole discretion. Unless specifically indicated otherwise, these Datasets are provided to you under a Creative Commons Attribution 4.0 International License (CC BY 4.0), with the additional terms below. The basic terms applicable to the CC BY 4.0 license may be accessed here. By downloading or using the Datasets, you agree to comply with the terms of the CC BY 4.0 license, as well as the following mandatory and binding addition: Any dispute relating to the interpretation or application of this license shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the UNCITRAL Arbitration Rules. The parties shall accept the arbitral award as final. |
| Permission type | Publicly accessible |
| Prohibited uses | You shall not attempt to de-anonymise the Datasets or use the Datasets in a manner that falsifies or misrepresents their content. You shall not, in connection with your use of the Datasets published on data.who.int, state or imply that WHO endorses, or is affiliated with, you, or that WHO endorses your use of data.who.int, or any content, output, or analysis resulting from or related to the data.who.int, or any entity, organization, company, product or services. |
| Citation | World Health Organization 2025 data.who.int, WHO TB dashboard [Dashboard]. https://data.who.int/dashboards/tuberculosis/ |
| Disclaimer | WHO reserves the right at any time and from time to time to modify or discontinue, temporarily or permanently, the Datasets, or any means of accessing or utilizing the Datasets with or without prior notice to you. Maps All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas). The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the accuracy of the Datasets. However, the Datasets are being provided without warranty of any kind, either expressed or implied. You will be solely responsible for your use of the Datasets. In no event shall WHO be liable for any damages arising from such use. For full disclaimers, terms of use and your indemnification of WHO, please visit Terms and Conditions. |